

## Cinqair® (reslizumab)



When requesting Cinqair® (reslizumab), the individual requiring treatment must be diagnosed with the following FDA-approved indication and meet the specific coverage guidelines and applicable safety criteria for the covered indication.

### FDA-approved indication

- Cinqair® (reslizumab) is indicated for add-on maintenance treatment of individuals with severe asthma having an eosinophilic phenotype.

### Approved Off-label Compendial use

- None

### Coverage Guidelines

#### Severe Asthma with an Eosinophilic Phenotype

The individual must meet **all** of the following criteria for initial approval:

- Diagnosis of severe asthma having an eosinophilic phenotype
- Requires treatment to prevent asthma from becoming uncontrolled or remaining uncontrolled despite therapy with:
  - High-dose inhaled corticosteroid plus a long-acting beta2-agonist (LABA), OR
  - Leukotriene modifier/theophylline for the previous year, OR
  - Systemic corticosteroids for greater than or equal to 50% of the previous year
- Pretreatment blood eosinophil count greater than or equal to 400 cells/mcL
- Current non-smoker
- Greater than or equal to 18 years of age
- Is prescribed by an allergist, immunologist, or pulmonologist

The individual must meet **all** of the following criteria for reauthorization:

- Diagnosis of severe asthma having an eosinophilic phenotype
- Pretreatment blood eosinophil count greater than or equal to 400 cells/mcL
- Current non-smoker
- Has shown reduction in incidence of asthma exacerbations
- Greater than or equal to 18 years of age
- Is prescribed by an allergist, immunologist, or pulmonologist

**Approval duration for initial and reauthorization: 12 months**

## Dosing Recommendations

3mg/kg IV every 4 weeks

## References

1. Blue Cross Blue Shield of Arizona Medical Coverage Guidelines. Cinqair. July 2018.
2. Cinqair® prescribing information. Frazer, PA: Teva Respiratory, LLC: Revised May 2016.
3. Klasco RK (Ed): DRUGDEX® system. Thomson Micromedex, Greenwood Village, CO. Accessed August 28, 2018.
4. Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. *Eur Respir J*. 2014;43:343-73. Accessed August 28, 2018.
5. Bjermer L, Lemiere C, Maspero J et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil levels: a randomized phase 3 study. *Chest*. 2016;150(4):789-798. Accessed August 28, 2018.